Gabapentin Capsule
Product Images NDC 70518-3329

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Gabapentin (NDC 70518-3329). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Mm2 (Gabapentin 300mg 70518 3329 01)

Label for Gabapentin 300 mg oral capsule, quantity of 1, repackaged by RemedyRepack Inc. The label includes NDC 70518-3329-01 and manufacturer information for Ascend Labs, LLC, Montvale, NJ. It provides storage instructions and a reminder to keep medication out of children's reach.*

FDA Label Image

Gabapentin 300mg 70518 3329 02

Gabapentin 300 mg capsule bottle label showing quantity of 270 capsules. The label includes the product NDC 70518-3329-02, manufacturer Ascend Labs, LLC, Montvale, NJ, and repackager RemedyRepack Inc., Indiana, PA. Storage instructions and a QR code are also visible, with dosage form as oral capsules.*

FDA Label Image

Remedy_label (Remedy Label)

Label for Gabapentin 300 mg capsules by RemedyRepack Inc. The label shows the product name, strength (300 mg), dosage form (capsule), and quantity (100). It includes NDC number 70518-3329-00, repackaging and manufacturing information, and a QR code. Usage directions reference the package insert.*

FDA Label Image

Gabapentin-equation (Gabapentin Equation)

A formula illustrating the calculation of creatinine clearance (CLCr) involving age, weight, serum creatinine, and an adjustment factor for female patients. This is a mathematical expression, not a medication label or packaging.*

FDA Label Image

Gabapentin-fig1 (Gabapentin Fig1)

A line graph showing mean pain score over 8 weeks comparing Placebo versus Gabapentin 3600 mg/day. The horizontal axis represents time in weeks, divided into a 4-week dose titration period and a 4-week fixed dose period. The vertical axis shows the mean pain score from 0 to 10. Gabapentin scores decrease steadily, while the Placebo group remains relatively constant.*

FDA Label Image

Gabapentin-fig2 (Gabapentin Fig2)

A line graph showing mean pain scores over a 7-week period with a 3-week dose titration followed by a 4-week fixed dose period. It compares placebo and two Gabapentin doses (1800 mg/day and 2400 mg/day), illustrating changes in pain scores across weeks for each group.*

FDA Label Image

Gabapentin-fig3 (Gabapentin Fig3)

A bar chart titled 'Proportion of Responders (patients with ≥ 50% reduction in pain score) at Endpoint: Controlled PHN Studies' comparing placebo (PBO) with gabapentin (GBP) doses in two studies. Study 1 shows 12% responders for PBO and 29% for GBP 3600. Study 2 shows 14% for PBO, 32% for GBP 1800, and 34% for GBP 2400. Statistical significance markers indicate p < 0.01 and p < 0.001 for some comparisons.*

FDA Label Image

Gabapentin-fig4.jpg (Gabapentin Fig4)

A scatter plot chart depicting differences (%) on the y-axis and daily dose (mg) on the x-axis for three different studies labeled a, b, and c. The chart shows data points for daily doses of approximately 600, 900, 1200, and 1800 mg, with varying difference percentages for each study group indicated by distinct square markers in black, gray, and white.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.